Redmond Asset Management’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.92M Buy
200,203
+1,389
+0.7% +$18.4K 0.73% 37
2026
Q1
$2.74M Buy
198,814
+6,510
+3% +$98.1K 0.75% 35
2025
Q4
$3.47M Sell
192,304
-411
-0.2% -$7.38K 0.88% 29
2025
Q3
$3.57M Buy
192,715
+3,078
+2% +$48.4K 0.88% 29
2025
Q2
$3.03M Buy
189,637
+75,320
+66% +$1.34M 0.72% 40
2025
Q1
$2.22M Buy
+114,317
New +$2.41M 0.57% 56

Other funds holding CLBT

Redmond Asset Management's CLBT Position: Q2 2026 in Review

Redmond Asset Management increased its Cellebrite (CLBT) stake by 0.7% in Q2 2026, buying an estimated $18.4K and bringing the position to 200,203 shares worth $2.92M. The position accounts for 0.73% of the portfolio, ranked #37.

Redmond Asset Management first reported a position in CLBT in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.57M in Q3 2025. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Redmond Asset Management held 200,203 shares of Cellebrite worth $2.92M as of Q2 2026.
  • Redmond Asset Management bought 1,389 Cellebrite shares in Q2 2026, an estimated $18.4K.
  • Cellebrite made up 0.73% of Redmond Asset Management's portfolio in Q2 2026, its #37 holding.
  • Redmond Asset Management first reported a position in Cellebrite in Q1 2025 and has held it in 6 quarters since.
  • Redmond Asset Management's Cellebrite position peaked at $3.57M in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Redmond Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.